more

Vericel (VCEL)

(Delayed Data from NSDQ)

$54.00 USD

+3.97 (7.94%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $54.06 +0.06 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Zacks News

Vericel Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on December 19,2019

Vericel has been struggling lately, but the selling pressure may be coming to an end soon.

VCELPositive Net Change

medical

Stock Market News for Nov 6, 2019

by Zacks Equity Research Published on November 06,2019

Wall Street made nominal progress on Nov 5, given the record highs major indexes reached on Monday.

Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research Published on April 30,2019

Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VCELPositive Net Change

What Makes Vericel (VCEL) a New Buy Stock

by Zacks Equity Research Published on March 06,2019

Vericel (VCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

VCELPositive Net Change

Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up

by Zacks Equity Research Published on February 26,2019

Vericel (VCEL) beat estimates for earnings as well as revenues in fourth-quarter 2018. Shares up in pre-market trading.

VCELPositive Net Change

biotechs

What's in Store for Vericel (VCEL) This Earnings Season?

by Zacks Equity Research Published on February 22,2019

On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.

biotechs

Bull or Bear: Your Investment Strategy for 2019

by Sejuti Banerjea Published on January 04,2019

Whether you're a bull or a bear, it may be a good idea to go defensive about now.

Zacks.com featured highlights include: Alteryx, Vericel, Mitek and Materialise

by Zacks Equity Research Published on January 03,2019

Zacks.com featured highlights include: Alteryx, Vericel, Mitek and Materialise

4 Stocks With Recent Price Strength to Maximize Your Gains

by Zacks Equity Research Published on January 02,2019

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on December 27,2018

Is (VCEL) Outperforming Other Medical Stocks This Year?

VCELPositive Net Change

5 Nasdaq Composite Stocks That Braved the Index's Bloodbath

by Nalak Das Published on December 26,2018

Despite a plummeting Nasdaq Composite, a few companies have survived the turbulence because of their internal strengths.

4 Healthcare Stocks That Popped More Than 100% in 2018

by Sapna Bagaria Published on December 19,2018

Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.

medical

Zacks.com featured highlights include: TEGNA, Vericel, Mobile Mini and Splunk

by Zacks Equity Research Published on December 19,2018

Zacks.com featured highlights include: TEGNA, Vericel, Mobile Mini and Splunk

4 Best Stocks That Flaunt Superb Earnings Acceleration

by Tirthankar Chakraborty Published on December 18,2018

Studies show that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.

biotechs

Four Biotech Stocks That Popped More Than 50% in 2018

by Zacks Equity Research Published on December 18,2018

The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.